We have changed our visitation policy for the safety of our patients and staff. Click here for the updated visitation policy and click here for information about COVID-19.

[LCID Study Number: 2018-084CIRB]

S1900A, A Phase II Study of Rucaparib in Patients with Genomic LOH High And/Or Deleterious BRCA1/2 Mutation Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung-MAP Sub-Study)

Targeted Treatment (rucaparib) for Advanced Non-Small Cell Lung Cancer

This study is being done to answer the following question: Can we lower the chance of your lung cancer growing or spreading by using a drug that targets a biomarker present in your tumor?We are doing this study because we want to find out if this approach is better or worse than the usual approach for your lung cancer. The usual approach for patients who are not in a study is treatment with chemotherapy or immunotherapy drugs.

Primary Contact Email: [email protected]

Primary Contact Phone: 781-744-3071